title: Biweekly THP-COP therapy for newly diagnosed peripheral T-cell lymphoma patients.
abstract: Pirarubicin tetrahydropyranyl adriamycin (THP-ADR) is an analogue of doxorubicin. This agent exhibits activity against some doxorubicin-resistant cell lines. We performed a phase II study of biweekly THP-COP [50 mg/m(2) pirarubicin, 750 mg/m(2) cyclophosphamide, 1.4 mg/m(2) vincristine (2.0 mg maximum) on day 1, and 100 mg/body predonisolone on days 1-5] in patients with peripheral T-cell lymphoma (PTCL). Seventeen patients with newly diagnosed PTCL were enrolled. Histological diagnoses were of PTCL, not otherwise specified (n = 5), or angioimmunoblastic T-cell lymphoma (n = 12). All diagnostic specimens including those of the historical control group were centrally reviewed by hematological pathologists. All patients received six cycles of biweekly THP-COP. The patient group included 13 male and 4 female patients, with a median age of 62 years. The median follow-up time in surviving patients was 30 months. Overall response rate was 94% with 15 cases of complete remission (88%). The 3-year progression-free survival and overall survival rates were 57% and 75%, respectively. The most frequent adverse events associated with biweekly THP-COP were leukocytopenia (100%), neutropenia (100%), and lymphopenia (100%), followed by alopecia (92%) and anaemia (88%). All of these occurred only transiently, and the patients subsequently recovered. Biweekly THP-COP is a safe and promising therapy for patients with newly diagnosed PTCL. This study is registered in a public database (UMIN000010485).
authors: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
authors: Naoto
authors: N
authors: Tomita
authors: Fumio
authors: F
authors: Kodama
authors: Naoko
authors: N
authors: Tsuyama
authors: Seiji
authors: S
authors: Sakata
authors: Kengo
authors: K
authors: Takeuchi
authors: Daisuke
authors: D
authors: Ishibashi
authors: Satoshi
authors: S
authors: Koyama
authors: Yoshimi
authors: Y
authors: Ishii
authors: Wataru
authors: W
authors: Yamamoto
authors: Hirotaka
authors: H
authors: Takasaki
authors: Maki
authors: M
authors: Hagihara
authors: Hideyuki
authors: H
authors: Kuwabara
authors: Masatsugu
authors: M
authors: Tanaka
authors: Chizuko
authors: C
authors: Hashimoto
authors: Etsuko
authors: E
authors: Yamazaki
authors: Hideyuki
authors: H
authors: Koharazawa
authors: Katsumichi
authors: K
authors: Fujimaki
authors: Rika
authors: R
authors: Sakai
authors: Shin
authors: S
authors: Fujisawa
authors: Yoshiaki
authors: Y
authors: Ishigatsubo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy*; D008231:Lymphopenia / Q000139:chemically induced; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D011379:Prognosis; D016019:Survival Analysis; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects; D055815:Young Adult
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C027260:pirarubicin
keywords: THP-COP-14; clinical study; peripheral T-cell lymphomas